Vaxxel
Vaxxel is dedicated to developing innovative vaccines against respiratory infections, focusing on intranasal live attenuated multivalent vaccines for diseases like bronchiolitis and pneumonia. The company aims to address high burdens of disease in children and older adults with its advanced vaccine platforms and candidates.
Industries
Nr. of Employees
small (1-50)
Products
Bivalent intranasal live-attenuated RSV/HMPV vaccine candidate
A bivalent live-attenuated vaccine candidate designed for intranasal administration that expresses F proteins from respiratory syncytial virus and human metapneumovirus, demonstrated to be infectious and replicative in airway models and protective in animal challenge studies.
Bivalent intranasal live-attenuated RSV/HMPV vaccine candidate
A bivalent live-attenuated vaccine candidate designed for intranasal administration that expresses F proteins from respiratory syncytial virus and human metapneumovirus, demonstrated to be infectious and replicative in airway models and protective in animal challenge studies.
Services
Preclinical vaccine R&D and in vivo proof-of-concept
Design and execution of preclinical efficacy and safety studies for intranasal live-attenuated respiratory vaccine candidates, including challenge models and immunogenicity assessment.
Viral vaccine process development and GMP manufacturing readiness
Cell-culture process development on Vero cell substrates and process optimization aimed at GMP-compliant production of live viral vaccines.
Preclinical vaccine R&D and in vivo proof-of-concept
Design and execution of preclinical efficacy and safety studies for intranasal live-attenuated respiratory vaccine candidates, including challenge models and immunogenicity assessment.
Viral vaccine process development and GMP manufacturing readiness
Cell-culture process development on Vero cell substrates and process optimization aimed at GMP-compliant production of live viral vaccines.
Expertise Areas
- Live-attenuated vaccine development
- Intranasal vaccine delivery and mucosal immunology
- Preclinical efficacy and safety assessment
- Viral vector engineering and reverse genetics
Key Technologies
- Reverse genetics for RNA viruses
- Live-attenuated viral vaccine design
- Intranasal delivery platforms
- Human airway epithelium infection models